Good Medicine: Europe Set for $2 Billion of Investments in Fourth-Quarter 2016 Life Science Capital/MRO Project Starts

SUGAR LAND--October 6, 2016--Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--As the North American Pharmaceutical-Biotech Industry, which includes coverage of pharmaceuticals, biologicals, medical devices and cosmetics, continues to return a healthy capital expenditures (capex) investment profile, Europe's volume of project activity continues to impress. During the last three months of 2016, more than $2 billion worth of projects are expected to launch construction on the continent.

Within this article: Details on some of the highest-valued projects set to begin construction in Europe's Pharmaceutical-Biotech Industry.